Corbus Pharmaceuticals Net Income Over Time
| CRBP Stock | USD 17.95 0.48 2.75% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Corbus Pharmaceuticals Performance and Corbus Pharmaceuticals Correlation. Corbus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Corbus Pharmaceuticals. If investors know Corbus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Corbus Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.71) | Quarterly Revenue Growth (1.00) | Return On Assets (0.29) | Return On Equity (0.51) |
The market value of Corbus Pharmaceuticals is measured differently than its book value, which is the value of Corbus that is recorded on the company's balance sheet. Investors also form their own opinion of Corbus Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Corbus Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Corbus Pharmaceuticals' market value can be influenced by many factors that don't directly affect Corbus Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Corbus Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Corbus Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Corbus Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Net Income Analysis
Compare Corbus Pharmaceuticals and related stocks such as ATyr Pharma, Trevi Therapeutics, and Cue Biopharma Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| TRVI | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (11.1 M) | (12.9 M) | (20.5 M) | (26.1 M) | (32.8 M) | (33.9 M) | (29.2 M) | (29.1 M) | (30.5 M) |
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (39 M) | (36.7 M) | (44.8 M) | (44.2 M) | (52.8 M) | (50.7 M) | (53.3 M) |
| ANTX | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (13.6 M) | (21.5 M) | (41.5 M) | (64.7 M) | (61.5 M) |
| BCAB | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (29 M) | (31.4 M) | (37.2 M) | (95.4 M) | (105.3 M) | (123.5 M) | (117.3 M) |
| KOD | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (17.1 M) | (27.9 M) | (41.4 M) | (46.7 M) | (133.1 M) | (267 M) | (333.8 M) | (260.5 M) | (247.5 M) |
| GLMD | (3.1 M) | (3.1 M) | (3.1 M) | (17.5 M) | (9.1 M) | (10.6 M) | (17 M) | (12.3 M) | (9.9 M) | (18.5 M) | (27.6 M) | (31.9 M) | (18.6 M) | (6.9 M) | (7.3 M) |
| AFMD | (14.3 M) | (14.3 M) | (14.3 M) | (26.1 M) | (259 K) | (20.2 M) | (32.2 M) | (30.2 M) | (19.5 M) | (32.4 M) | (41.4 M) | (57.5 M) | (86 M) | (105.9 M) | (100.6 M) |
| MREO | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (12.2 M) | (28.4 M) | (38.8 M) | (32 M) | (34.8 M) | (163.6 M) | 12.7 M | (34.2 M) | (29.5 M) | (30.9 M) |
| ADVM | (1.8 M) | (1.8 M) | (1.8 M) | (5.3 M) | (25.4 M) | (47.5 M) | (113.7 M) | (56.1 M) | (72.6 M) | (64.5 M) | (117.5 M) | (145.5 M) | (154.5 M) | (117.2 M) | (123 M) |
| NXTC | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (15.5 M) | (22.8 M) | (33.7 M) | (33.2 M) | (69.4 M) | (69.4 M) | (62.7 M) | (65.9 M) |
| CTMX | (15.1 M) | (15.1 M) | (15.1 M) | (15.1 M) | (30.3 M) | (35.4 M) | (58.9 M) | (43.1 M) | (84.6 M) | (102.2 M) | (32.9 M) | (80.6 M) | (97.3 M) | (569 K) | (597.5 K) |
| SPRO | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (10.2 M) | (25.5 M) | (46.1 M) | (41.7 M) | (60.2 M) | (77.5 M) | (91.3 M) | (48 M) | 22.8 M | 23.9 M |
| ASMB | (8.8 M) | (34.3 M) | (24.8 M) | (19.4 M) | (23.8 M) | (28.5 M) | (44.3 M) | (42.8 M) | (90.8 M) | (97.6 M) | (59.5 M) | (129.9 M) | (92.1 M) | (61.2 M) | (64.3 M) |
| ZVSA | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (8.9 M) | (759.1 M) | (98.3 M) | (103.2 M) |
| OCEA | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (232 K) | (1.7 M) | (62.3 M) | 565.5 K | 508.9 K | 534.4 K |
| ZURA | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 8.4 M | 3.5 M | (60.4 M) | (57.3 M) |
| ELEV | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (5.9 M) | (17.3 M) | (32 M) | (95.1 M) | (45.7 M) | (48 M) |
| DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (179.5 M) |
| ABOS | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.9 M) | (7.3 M) | (181.7 M) | (40.5 M) | (52.4 M) | (55 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (96.1 M) |
| INZY | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (18.6 M) | (55.8 M) | (56.4 M) | (65.4 M) | (71.2 M) | (74.7 M) |
Corbus Pharmaceuticals and related stocks such as ATyr Pharma, Trevi Therapeutics, and Cue Biopharma Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Corbus Pharmaceuticals financial statement analysis. It represents the amount of money remaining after all of Corbus Pharmaceuticals Holding operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Corbus Pharmaceuticals Holding | CRBP |
| Classification | Cannabis |
| Location | Massachusetts; U.S.A |
| Exchange | NASDAQ Exchange |
USD 17.95
Additional Tools for Corbus Stock Analysis
When running Corbus Pharmaceuticals' price analysis, check to measure Corbus Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Corbus Pharmaceuticals is operating at the current time. Most of Corbus Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Corbus Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Corbus Pharmaceuticals' price. Additionally, you may evaluate how the addition of Corbus Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.